Posted inBusiness Insights
Cipla Reaffirms Full-Year Profit Guidance as $1 Billion US Revenue Target Paves Way for FY27 Growth Ramp-Up
Indian pharmaceutical major Cipla Limited announced it is maintaining its full-year EBITDA margin guidance of 18.5% to 20%, anchored by a projected U.S. sales run rate of $1 billion by…
